Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Peposertib + Radium Ra 223 dichloride |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Peposertib | M3814|M-3814|Nedisertib|MSC2490484A | DNA_PK Inhibitor 9 | Peposertib (MSC2490484A) is a DNA-dependent protein kinase (DNA-PK) inhibitor that blocks DNA damage repair, which may lead to antitumor activity by sensitizing cancer cells to radiation and agents that induce DNA double strand breaks (PMID: 32220971). | |
Radium Ra 223 dichloride | Xofigo | BAY 88-8223|alpharadin|BAY88-8223|Radium 223 Dichloride | Radium Ra 223 dichloride is a radium-based radiopharmaceutical that targets bone via incorporation into bony matrix, and results in DNA double strand breaks and tumor regression in bone (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04071236 | Phase Ib/II | Peposertib + Radium Ra 223 dichloride Radium Ra 223 dichloride Avelumab + Peposertib + Radium Ra 223 dichloride | Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | Recruiting | USA | 0 |